Skip to content
Screener

Income Tax at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.21B+27.1%
United Community Banks logo
United Community BanksUCB
$33.53M+54.0%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$79K-4.8%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$18K+12.5%

Segments

By geography

See full
United States$0.210.0%

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.21B+201%
Enterprise value$7.31B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Immunovant, Inc.’s 10-Q, filed February 6, 2026.

Filed
Feb 6, 2026, 7:24 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001764013-26-000011
Line itemThree Months Ended December 31, 2025Three Months Ended December 31, 2024Nine Months Ended December 31, 2025Nine Months Ended December 31, 2024
Total operating expenses114,362114,302373,348324,327
Interest income, net(5,333)(4,590)(17,274)(17,844)
Other (income) expense, net541,258(1,383)600
Loss before provision for income taxes(109,083)(110,970)(354,691)(307,083)
Provision for income taxes1,5521523,059308
Net loss$(110,635)$(111,122)$(357,750)$(307,391)
Net loss per common share – basic and diluted$(0.61)$(0.76)$(2.04)$(2.10)
Weighted-average common shares outstanding – basic and diluted181,513,386146,922,338175,414,491146,560,414

Item 1. Financial Statements (unaudited)

FAQ

What is Immunovant, Inc.'s income tax?
Immunovant, Inc. (IMVT) reported income tax of $1.55M in Q4 2025.
How has Immunovant, Inc.'s income tax changed year-over-year?
Immunovant, Inc.'s income tax increased by 921.1% year-over-year, from $152K to $1.55M.
What is the long-term trend for Immunovant, Inc.'s income tax?
Over 2 years (2022 to 2025), Immunovant, Inc.'s income tax has grown at a 225.5% compound annual growth rate (CAGR), from -$84K to $890K.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.

Ask your AI about Immunovant, Inc.'s income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude